TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
J Cardiovasc Pharmacol Ther. 2010 Sep;15(3):210-9. doi: 10.1177/1074248410366448. Epub 2010 May 18.
Arterial and venous thromboembolism account for significant morbidity and mortality worldwide. Warfarin, and other vitamin K antagonists (VKAs), have been the only class of oral anticoagulants currently in clinical use and have been so for over 50 years. Although warfarin is effective in preventing thromboembolism, its use is limited by its narrow therapeutic index that necessitates frequent monitoring and dose adjustments resulting in considerable inconvenience to patients and clinicians. There are now several orally administered anticoagulants in late stages of clinical development that may offer effective, safer, and more convenient anticoagulation. This review summarizes and compares data on novel anticoagulants in the prophylaxis and treatment of venous thromboembolism, acute coronary syndromes, and the prevention of stroke in patients with atrial fibrillation.
动脉和静脉血栓栓塞症在全球范围内导致了大量的发病率和死亡率。华法林和其他维生素 K 拮抗剂（VKAs）一直是目前唯一一类在临床使用的口服抗凝剂，已经使用了超过 50 年。尽管华法林在预防血栓栓塞方面有效，但由于其治疗指数狭窄，需要频繁监测和剂量调整，这给患者和临床医生带来了相当大的不便。目前有几种口服抗凝剂处于临床开发的后期阶段，它们可能提供更有效、更安全和更方便的抗凝治疗。这篇综述总结并比较了新型抗凝剂在静脉血栓栓塞症、急性冠状动脉综合征和房颤患者中风预防中的预防和治疗数据。
